Abstract Number: 2578 • ACR Convergence 2023
Machine Learning Identifies New Sporadic Inclusion Body Myositis Endotypes Associated with Unique Autoantibody Profiles
Background/Purpose: Sporadic inclusion body myositis (sIBM) is a subset of autoimmune inflammatory myopathies (AIM) that is often challenging to diagnose. The objective of this study…Abstract Number: 0287 • ACR Convergence 2023
6-Minute Walk Distance Associates with Physiologic Measures and Physician/Patient Reported Outcomes in Myositis Related Interstitial Lung Disease
Background/Purpose: The 6 minute walk distance (6MWD) provides a global evaluation of sub-maximal exercise capacity that is easily performed and highly reproducible, and is used…Abstract Number: 0664 • ACR Convergence 2023
Quantitative Hand Held Dynamometry to Assess Muscle Strength in Scleroderma Associated Myopathy
Background/Purpose: Manual muscle strength testing can be challenging in SSc associated myopathy (SSc-AM) due to contractures or skin tightening. Since there is currently no validated…Abstract Number: 1169 • ACR Convergence 2023
All-cause Mortality and Risk Factors for Death in a Large Multi-center Prospective Registry Cohort of Idiopathic Inflammatory Myositis in China
Background/Purpose: Our study depicted the mortality and independent risk factors of IIM patients in a large multi-center prospective registry cohort in China. Methods: Patients registered…Abstract Number: 1927 • ACR Convergence 2023
Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review
Background/Purpose: Anti-synthetase syndrome (ASS) is a chronic autoimmune inflammatory condition, characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud's phenomenon and mechanic's hands. This systematic…Abstract Number: 1965 • ACR Convergence 2023
Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Idiopathic Inflammatory Myopathies: Results from the COVAD Study
Background/Purpose: Disease activity assessment is key in the management of patients with idiopathic inflammatory myopathies (IIM). However, patients' perception of disease may differ from clinicians.…Abstract Number: 2579 • ACR Convergence 2023
Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: This study aimed to validate the Patient Reported Outcome Measurement Information System (PROMIS) tools in patients with adult and juvenile idiopathic inflammatory myopathies (IIM/JIIM)…Abstract Number: 028 • 2023 Pediatric Rheumatology Symposium
Achieving Medication-Free Remission in Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis. Systemic immunosuppression is needed. Evidence is limited…Abstract Number: 064 • 2023 Pediatric Rheumatology Symposium
Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis
Background/Purpose: Increasing attention has been recently paid to the development of parent- and child-centered composite DAS for the assessment of health status of children with…Abstract Number: 100 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): II – A Longitudinal Assessment of Muscle Strength by Manual Muscle Test (MMT) and Childhood Myositis Assessment Scale (CMAS) Tools
Background/Purpose: Muscle weakness is often progressive and persistent in Juvenile Dermatomyositis (JDM). Muscle strength testing is useful for evaluating severity of muscle weakness. There is…Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…Abstract Number: L10 • ACR Convergence 2022
Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)
Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is a severe form of myositis characterized by muscle weakness and elevated creatine kinase levels in serum. The most frequent…Abstract Number: 0155 • ACR Convergence 2022
Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis
Background/Purpose: Calcinosis is a complication of the idiopathic inflammatory myopathies (IIM) in which calcium salts are deposited in and around soft tissue, which can impact…Abstract Number: 0178 • ACR Convergence 2022
Muscle Fibres Play a Critical Role in Therapeutic Response of Myositis to Glucocorticoids Through Polarisation of the Inflammatory Infiltrate by a Paracrine Mechanism
Background/Purpose: Glucocorticoids (GC) are the first line treatment for myositis patients. They improve muscle strength, yet muscle recovery is generally partial and long lasting treatment…Abstract Number: 1864 • ACR Convergence 2022
Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response
Background/Purpose: Hepatitis B (HBV) screening in patients with autoimmune conditions is vital prior to the initiation of immunosuppressive therapy given the risk of HBV reactivation.…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 28
- Next Page »